Ashley Chan

Ashley Chan joined the OncLive team as an assistant editor in 2025 after previously working on the CURE editorial team since 2023.

Email: achan@mjhlifesciences.com

Articles

Dr O’Shaughnessy on the Utility of the MammaPrint Assay in HR+ Breast Cancer

September 5th 2025

Joyce O’Shaughnessy, MD, discussed data that support the use of the MammaPrint assay in predicting chemotherapy benefit in HR-positive breast cancer.

Dr Tashi on Differentiating Characteristics of Elenestinib in Indolent Systemic Mastocytosis

September 5th 2025

Tsewang Tashi, MD, discusses the aspects of elenestinib that differentiate it from avapritinib in the management of indolent systemic mastocytosis.

Chemoradiotherapy Data, PCI Controversy, and Translational Research Advance SCLC Care

September 5th 2025

Misty D. Shields, MD, PhD, discusses the inefficacy of concurrent immunotherapy and chemoradiation in lung cancer and the debate surrounding PCI in SCLC.

Dr Gellhaus on the Significance of Prostate Cancer Awareness Month

September 4th 2025

Paul Gellhaus, MD, discusses the clinical implications of prostate cancer screening in recognition of Prostate Cancer Awareness Month.

Dr Sands on Toxicities Associated With Tarlatamab in SCLC

September 4th 2025

Jacob Sands, MD, discusses ways to manage the toxicities associated with the DLL3 inhibitor tarlatamab in the treatment of patients with SCLC.

Ziftomenib With 7+3 Shows Early Promise in Newly Diagnosed NPM1-Mutated/KMT2A-Rearranged AML

September 4th 2025

The combination of ziftomenib and cytarabine/daunorubicin showed a manageable safety profile with early efficacy in NPM1-mutated and KMT2A-rearranged AML.

Olutasidenib Monotherapy Yields Responses in Primary Refractory IDH1-Mutant AML

September 4th 2025

A post hoc analysis demonstrated the efficacy of olutasidenib monotherapy in primary refractory patients with IDH1-mutant AML.

Dr Klempner on the Safety Profile of Givastomig Plus Nivolumab and mFOLFOX6 in Gastric, Esophageal, and GEJ Cancer

September 3rd 2025

Samuel J. Klempner, MD, details the safety profile of givastomig/nivolumab and mFOLFOX6 in CLDN18.2-positive gastric, esophageal, and GEJ cancers.

Dr Aldoss on MRD Negativity Outcomes With Ponatinib vs Imatinib in Newly Diagnosed Ph+ ALL

September 3rd 2025

Ibrahim T. Aldoss, MD, discusses MRD negativity outcomes with ponatinib vs imatinib in newly diagnosed Philadelphia chromosome–positive ALL.

GD2-Directed CAR T-Cell Therapy Generates Early Antitumor Activity in H3K27M-Mutant Diffuse Midline Glioma

September 3rd 2025

Michelle Monje, MD, PhD, highlights early efficacy data with a GD2-directed CAR T-cell therapy for H3K27M-mutant diffuse midline gliomas.

Zanzalintinib Plus Nivolumab Generates Early Antitumor Activity in Untreated Advanced ccRCC

September 3rd 2025

Jad Chahoud, MD, MPH, discusses preliminary efficacy data with zanzalintinib plus nivolumab with/without relatlimab in untreated, advanced clear cell RCC.

Dr Van Tine on Olaparib Plus Temozolomide in Advanced Uterine Leiomyosarcoma

September 2nd 2025

Brian A. Van Tine, MD, PhD, discussed trial findings with olaparib plus temozolomide in advanced uterine leiomyosarcoma following prior chemotherapy.

Dr Tarhini on the Rationale for Studying Vidutolimod Plus Pembrolizumab in Melanoma

September 2nd 2025

Ahmad Tarhini, MD, PhD, discussed the rationale for evaluating preoperative pembrolizumab plus vidutolimod in macroscopic, resectable stage III melanoma.

Dr Haas on the Rationale for Evaluating Adjuvant Pembrolizumab in Clear Cell RCC

September 2nd 2025

Naomi B. Haas, MD, details the rationale for evaluating adjuvant pembrolizumab monotherapy for the treatment of patients with clear cell RCC.

Dr Schlechter on the Potential Future Implications of Botensilimab and Balstilimab in MSS mCRC

September 2nd 2025

Benjamin L. Schlecter, MD, discusses the potential next steps in research for botensilimab for the treatment of patients with metastatic colorectal cancer.

FDA Grants Type A Meeting to Discuss RP1 Plus Nivolumab in Advanced Melanoma

September 2nd 2025

The FDA scheduled a Type A meeting with the developer of RP1 to discuss the CRL that was granted to RP1 plus nivolumab for advanced melanoma.

Zongertinib Earns Chinese Approval for Unresectable, Locally Advanced, HER2-Mutant NSCLC

September 2nd 2025

China’s NMPA approved zongertinib tablets for unresectable, locally advanced or metastatic, previously treated NSCLC with HER2 mutations.

Ongoing Trials and Practical Insights Shape CDK4/6 Inhibitor Use in HR+ Metastatic Breast Cancer

August 30th 2025

Neelam V. Desai, MD, discusses the role of first-line CDK4/6 inhibitors in HR-positive, HER2-negative and HER2-positive metastatic breast cancer.

Dr Arafat on Evolving Neoadjuvant Treatment Strategies in MIBC

August 29th 2025

Waddah Arafat, MD, discusses how the use of neoadjuvant chemotherapy in MIBC has changed relative to the addition of immunotherapy to this paradigm.

Dr Hammers on Considerations for Assessing TKI/Immunotherapy Response in ccRCC

August 29th 2025

Hans Hammers, MD, PhD, discusses factors that may influence depth of response to IO/TKI or IO/IO therapy in advanced clear cell renal cell carcinoma.